Aptus Capital Advisors, LLC - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 46 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2022. The put-call ratio across all filers is 0.16 and the average weighting 0.0%.

Quarter-by-quarter ownership
Aptus Capital Advisors, LLC ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q3 2022$46,000
+64.3%
10,360
+1.5%
0.00%0.0%
Q2 2022$28,000
-33.3%
10,210
-18.3%
0.00%0.0%
Q1 2022$42,000
-16.0%
12,5000.0%0.00%
-50.0%
Q4 2021$50,000
-5.7%
12,500
-21.9%
0.00%
+100.0%
Q3 2021$53,000
-24.3%
16,000
-12.8%
0.00%
-50.0%
Q2 2021$70,000
+14.8%
18,350
+14.3%
0.00%0.0%
Q1 2021$61,000
-60.4%
16,050
-53.0%
0.00%
-71.4%
Q4 2020$154,00034,1500.01%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q4 2022
NameSharesValueWeighting ↓
Weaver Consulting Group 130,000$437,0000.21%
Ikarian Capital, LLC 304,161$1,022,0000.13%
ABNER HERRMAN & BROCK LLC 265,000$890,0000.12%
S.C. Financial Services, Inc. 15,285$51,0000.06%
JMAC ENTERPRISES LLC 45,430$153,0000.04%
CFO4Life Group, LLC 12,000$40,0000.01%
OSAIC HOLDINGS, INC. 10,839$1,329,0000.00%
INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC 3,000$10,0000.00%
BOOTHBAY FUND MANAGEMENT, LLC 29,186$98,0000.00%
RAYMOND JAMES & ASSOCIATES 190,403$640,0000.00%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders